Milad Alucozai’s Post

This $66m oversubscribed series B for ShiraTronics, Inc. brings the yearly subtotal raised in #neuromodulation to $618 million. That's +10% on this time last year, and a significant increase on the 2022 numbers. Yes, in many ways, and for many reasons this has been a challenging year, however you can't ignore this continued, and increasing interest in #neurotech from investors. Any start-ups in this space currently raising, or planning to raise should be encouraged by these stats. IMO there is no other area of #medtech that comes close to the sheer potential that Neuromod presents. Norwest Venture Partners led this investment round, and Shiratronics will use the funds to support their recently launched pivotal trial "RELIEV-CM2” to evaluate their Migraine Therapy System. The fnancing is also intended to fund initial commercial launch as they seek FDA PMA. Big congratulations to Rob Binney and the Shiratronics gang. UPDATED: Just seen a $27m raise from Nyxoah too. That's some 24hrs for Neuromod. Congratulations all

📰 New article on our #blog! Two weeks ago we published an article on Dry AMD explaining a patient's journey. Now is the time to delve deeper into the experience of living with Wet AMD. Take a look at the article: https://lnkd.in/eXgvjCpf Keep an eye open for more. 😉 #InvestInMantisPhotonics #TheEyeIsTheWindowToYourHealth #Startup #HyperspectralCamera #EarlyDiagnosisRevolution #OphthalmologicDisease #NeurologicalDisorders #AMD

Neuroscience firm Engrail Therapeutics bags $157M Series B funding for clinical development of therapies San Diego-headquartered neurosciences firm Engrail Therapeutics has secured $157 million in Series B funding co-led by F-Prime Capital, Forbion, and Norwest Venture Partners. Healthcare investor Eights Road Ventures, RiverVest Venture Partners, and Red Tree Venture Capital also participated in the round. The funding will propel Engrail to advance its pipeline through multiple stages of clinical development, the company said in a statement. It is developing therapies for the treatment of diseases with unmet medical needs, including anxiety disorders, depression, post-traumatic stress disorder, and rare neurodegenerative diseases. "Congratulations to Engrail Therapeutics on securing $157 million in Series B funding, co-led by F-Prime Capital, Forbion, and Norwest Venture Partners, along with participation from other esteemed investors! This substantial investment underscores the confidence in Engrail's innovative approach to addressing unmet medical needs in neuropsychiatric and neurodevelopmental diseases. With this funding, Engrail is well-equipped to advance its pipeline through clinical development stages, bringing hope to patients worldwide. We applaud Engrail's leadership team, including President and CEO Vikram Sudarsan, for their dedication and vision in driving the company's success," says Dr. Shishir Gupta, Founder and CEO of StartupLanes. Karoly Nikolich Ethan Schafer Lisa Toward Penelope Przekop Natalia Serrano Camilla Gomiero Wade Tejal Merchant Eve M. Taylor, PhD Rasesh Shah Anil Vootkur Quentin McCubbin Shannon Hafer Sean Kipperman #startup #funding #fundingnews #investment #startups #startuplanes #startupnews #investmentnews #startupbusiness #FinancingSuccess #InnovationJourney For rectification/nomination reach out to [email protected] or +91 7982899391. Kindly only contact us during office hours, i.e., 10 am- 6 pm (Monday to Saturday)

Neuroscience firm Engrail Therapeutics bags $157M Series B funding for clinical development of therapies San Diego-headquartered neurosciences firm Engrail Therapeutics has secured $157 million in Series B funding co-led by F-Prime Capital, Forbion, and Norwest Venture Partners. Healthcare investor Eights Road Ventures, RiverVest Venture Partners, and Red Tree Venture Capital also participated in the round. The funding will propel Engrail to advance its pipeline through multiple stages of clinical development, the company said in a statement. It is developing therapies for the treatment of diseases with unmet medical needs, including anxiety disorders, depression, post-traumatic stress disorder, and rare neurodegenerative diseases. "Congratulations to Engrail Therapeutics on securing $157 million in Series B funding, co-led by F-Prime Capital, Forbion, and Norwest Venture Partners, along with participation from other esteemed investors! This substantial investment underscores the confidence in Engrail's innovative approach to addressing unmet medical needs in neuropsychiatric and neurodevelopmental diseases. With this funding, Engrail is well-equipped to advance its pipeline through clinical development stages, bringing hope to patients worldwide. We applaud Engrail's leadership team, including President and CEO Vikram Sudarsan, for their dedication and vision in driving the company's success," says Dr. Shishir Gupta, Founder and CEO of StartupLanes. Karoly Nikolich Ethan Schafer Lisa Toward Penelope Przekop Natalia Serrano Camilla Gomiero Wade Tejal Merchant Eve M. Taylor, PhD Rasesh Shah Anil Vootkur Quentin McCubbin Shannon Hafer Sean Kipperman #startup #funding #fundingnews #investment #startups #startuplanes #startupnews #investmentnews #startupbusiness #FinancingSuccess #InnovationJourney For rectification/nomination reach out to [email protected] or +91 7982899391. Kindly only contact us during office hours, i.e., 10 am- 6 pm (Monday to Saturday)

Amber Therapeutics raises $100m - one of the largest series A's for a European Medtech 🇬🇧 💪 The UK-based medtech company has just closed their Series A financing round, raising $100 million (£80 million) from investors across the US and UK. This funding was led by New Enterprise Associates (NEA), and included F-Prime Capital, Lightstone Ventures, Intuitive Ventures, Oxford Science Enterprises, and 8VC. Amber is pioneering an adaptive #neuromodulation therapy, Amber-UI, to treat mixed urinary incontinence (MUI) - a condition affecting millions of women worldwide. Amber-UI is the first fully implantable therapy targeting the pudendal nerve, designed to address both urge and stress incontinence through a minimally invasive procedure. Aidan Crawley, CEO of Amber said: "Securing this significant financing round from such a blue-chip group of US and UK investors is a huge validation of our therapy value proposition and the quality of the team we have built". Amber-UI, powered by the Picostim System, offers a unique approach by dynamically adapting to physiological responses, aiming to restore normal bladder function. Early results from their initial study "Aura 2" look promising, showing safety and strong efficacy signals. #funding #neurotech

[#PrixGalienUSA] Since 2022, the Prix Galien Medstartup, which rewarded the most promising French companies in partnership with American firms, has become the Prix Galien Best Startup, opening the prize to all innovative startups worldwide. At Business France, we are proud that innovative French healthcare startup have been recognized, with 1 French winner among the 3 winners in this category over the past 2 years: 2023: Volta Medical with its innovative artificial intelligence solutions that enhance the diagnosis and treatment of cardiac disorders. 2022: Quantum Surgical SAS and its revolutionary technology offer minimally invasive solutions for tumor treatment, utilizing advanced imaging for precise interventions. Not forgetting all the Prix Galien Medstartup winners between 2013 and 2022. Here are some of those who have triumphed in the past: TreeFrog Therapeutics (in partnership with QC-Stem Consortium) - 2020 Wandercraft (in partnership with Shirley Ryan Ability Lab, Caltech, and Amberlabs) - 2020 E-Scopics (in partnership with The Ultrasonic Material Characterization) - 2020 Acticor Biotech (in partnership with Memorial Hermann) - 2021 Hemerion Therapeutics (in partnership with Mount Sinai) - 2021 Vivet Therapeutics (in partnership with Pfizer and Mirum) - 2021   🎉Congratulations to all these companies for their groundbreaking contributions to healthcare through their innovative discoveries and technologies! Roxane Valfort - Jonathan Moreil - Elsa Rive Boukadoum - Ludmilla Potiron - Bruno Cohen - Xinyi CAO - Marie-Astrid Sevilla - Jerome Revole -The Galien Foundation - Business France – Santé 🚀

HistoSonics, Inc. is honored to announce the completion of an oversubscribed $102 million Series D financing which will be used to accelerate category defining advancements to our non-invasive histotripsy platforms, support commercial growth in the US and in planned global markets, and initiate the company’s innovative, prospective BOOMBOX Master Study. The round was led by Alpha Wave Global, a world leader in growth stage investments, with participation from new investors Amzak Capital Management and HealthQuest Capital, and existing investors Johnson & Johnson Innovation JJDC Inc, Venture Investors Health Fund, Lumira Ventures, Hatteras Venture Partners, Yonjin Venture, the State of Wisconsin Investment Board, and others. We are excited to have such experienced investors join our team at HistoSonics, and whose investment reinforces our mission to impact patients’ lives with our current liver application and expanded use in kidney, pancreas, prostate, brain and other tumor types. #TeamHisto #Histotripsy #MinimallyInvasiveneIsntMinimalEnough https://lnkd.in/gZy6W9qK

Mumbai-based AI diagnostics startup Qure.ai has secured $65 million in a Series D funding round led by Lightspeed Venture Partners and 360 ONE Asset Management. The funds will fuel Qure.AI’s global expansion, including in the US, enhance its AI models, and support strategic acquisitions. The company’s AI-powered solutions, used across 3,000 imaging sites in over 90 countries, outperform human radiologists in diagnosing diseases like tuberculosis, lung cancer, and stroke. Qure.AI’s products are cleared by regulators in the US and EU, underscoring its global impact. #QureAI #AIHealthcare #SeriesDFunding #LightspeedVenture #DiagnosticsInnovation #AIinMedicine #GlobalExpansion #HealthTech #MedicalAI #Radiology #HealthcareInnovation #IndiaStartups #ArtificialIntelligence #MedicalImaging #TechFunding #HealthTechRevolution

Neurotech startup Juniper Biomedical raises $3m to develop solutions for pelvic health disorders 🧠 💪 With a successful $2 million seed funding round and an additional $1 million grant from the NIH SPARC Neuromod Prize, Juniper Biomedical is poised for growth and innovation. 🚀 Led by Auroral Holdings and supported by Atma Capital, Hub Angels, Beacon Angels, and other investors, the funding will propel the development and commercialisation of Juniper Biomedical's unique neuromodulation micro-implant technology. Their first application aims to provide long-term precision therapy for patients with mixed urinary incontinence (MUI), addressing a prevalent issue affecting millions. 🌐🩺 CEO and Co-Founder David Constantine said: “We are thrilled to have the support and confidence of our investors and NIH as we embark on the next phase of our journey to offer patients better care options. Our team will leverage these new funds to accelerate the development of transformative solutions for multiple care gaps in pelvic health.” #neurotech #neuromodulation #funding

Our friends at Galen Growth | Insights You Can Trust have released a thoughtful report about 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡’𝐬 𝐌𝐨𝐬𝐭 𝐈𝐦𝐩𝐚𝐜𝐭𝐟𝐮𝐥 𝐄𝐚𝐫𝐥𝐲-𝐒𝐭𝐚𝐠𝐞 𝐈𝐧𝐯𝐞𝐬𝐭𝐨𝐫𝐬 𝐢𝐧 𝐄𝐮𝐫𝐨𝐩𝐞. Some key points: ▶ Europe counts over 3,500 ventures and 3,000+ early-stage investors in Digital Health. 26.5% of these investors have made at least three investments since 2019. ▶Early-stage investors are crucial for startup development; since January 2019, 33% of venture capital and 85% of deals in Europe have focused on early-stage rounds. ▶Since 2019, 1,900 unique investors have participated in 1,472 early-stage deals in Europe, injecting a total of $7.1 billion. ▶Top 5 clusters for the most impactful early-stage investors: Medical Diagnostics, TechBio, and Patient Solutions. ▶ Leading disease areas for the most impactful early-stage investors: Oncology, Women’s Health, and Mental Health. 🥇 Most notable early-stage investors in Europe by deal volume: HTGF | High-Tech Gründerfonds Speedinvest Octopus Ventures Crista Galli Ventures Seedcamp Read on 👉 https://lnkd.in/dUQbhXD9 #healthinnovation #investors #VC #oncology #mentalhealth #digitalhealth #neurology #womenshealth #cardiovasculardiseases